The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report
Keyword(s):
Low Dose
◽
Keyword(s):
2020 ◽
Vol 18
(3)
◽
pp. e312-e314
◽
2017 ◽
Vol 15
(1)
◽
pp. e95-e97
◽
2015 ◽
Vol 13
(5)
◽
pp. e361-e364
◽